MX2017000578A - Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. - Google Patents

Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.

Info

Publication number
MX2017000578A
MX2017000578A MX2017000578A MX2017000578A MX2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A MX 2017000578 A MX2017000578 A MX 2017000578A
Authority
MX
Mexico
Prior art keywords
cerium oxide
radiation
oxide nanoparticles
cancer
treatment
Prior art date
Application number
MX2017000578A
Other languages
English (en)
Inventor
Baker Cheryl
Original Assignee
Biocurity Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocurity Holdings Inc filed Critical Biocurity Holdings Inc
Publication of MX2017000578A publication Critical patent/MX2017000578A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se dirige a métodos para el tratamiento de cáncer con una combinación de radiación, nanopartículas de óxido de cerio y al menos un agente quimioterapéutico. Las nanopartículas de óxido de cerio (CONPs) son cristales del tamaño de nanómetro de óxido de cerio, que varían típicamente entre aproximadamente un nanómetro a aproximadamente 20 nanómetros en la dimensión más larga. Los presentes métodos usan nanopartículas de óxido de cerio para mejorar la muerte de células cancerosas inducidas por radiación e inducidas por quimioterapia y también para reducir la toxicidad asociada con la terapia de radiación y quimioterapia.
MX2017000578A 2014-07-17 2015-07-17 Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico. MX2017000578A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
PCT/US2015/040869 WO2016011328A1 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Publications (1)

Publication Number Publication Date
MX2017000578A true MX2017000578A (es) 2017-07-20

Family

ID=55079076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000578A MX2017000578A (es) 2014-07-17 2015-07-17 Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.

Country Status (9)

Country Link
EP (2) EP3169312B1 (es)
JP (2) JP6706255B2 (es)
CN (2) CN106604719B (es)
AU (1) AU2015289504B2 (es)
BR (1) BR112017000800A8 (es)
CA (1) CA2955384C (es)
MX (1) MX2017000578A (es)
RU (2) RU2019133284A (es)
WO (1) WO2016011328A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
CA2955384C (en) * 2014-07-17 2024-03-12 Biocurity Holdings, Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
KR20200059188A (ko) * 2017-04-12 2020-05-28 비카쉬 제이. 바그완딘 내성 종양의 민감화를 위해 포사코나졸을 사용한 조성물, 패키징된 약제, 및 방법
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
MX2021003710A (es) * 2018-09-28 2021-08-19 Univ Colorado Regents Metodos para prevenir y tratar inflamacion y fibrosis pulmonar.
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
CN115996633A (zh) * 2020-04-30 2023-04-21 中佛罗里达大学研究基金会 消毒用可分配的纳米颗粒基组合物
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548A (zh) 2021-08-27 2024-03-05 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US20100166821A1 (en) * 2005-06-27 2010-07-01 Edward Via Virginia College Of Osteopathic Medicin Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
AU2009240470B8 (en) * 2008-04-25 2015-02-05 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
EA201290846A1 (ru) * 2010-03-01 2013-07-30 Интраоп Медикал Корпорейшн Лучевая терапия, комбинированная с сенсибилизаторами гипоксической клетки
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
WO2013151698A1 (en) * 2012-04-04 2013-10-10 Duke University Methods for using cerium oxide nanoparticles to mitigate or protect against radiation injury
DK2861212T3 (en) * 2012-06-13 2017-03-06 Cerion Llc Cerium oxide nanoparticles for the treatment of oxidative stress
KR20150090917A (ko) * 2012-12-06 2015-08-06 머크 샤프 앤드 돔 코포레이션 디술피드-차폐 전구약물 조성물 및 방법
US10463734B2 (en) * 2014-04-25 2019-11-05 The Regents Of The University Of Michigan Nanoparticle therapy in cancer
CA2955384C (en) * 2014-07-17 2024-03-12 Biocurity Holdings, Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Also Published As

Publication number Publication date
EP3169312B1 (en) 2020-09-02
BR112017000800A8 (pt) 2023-04-25
CN106604719B (zh) 2019-11-26
AU2015289504A1 (en) 2017-02-23
RU2017104909A3 (es) 2019-01-28
EP3169312A1 (en) 2017-05-24
EP3169312A4 (en) 2017-12-27
CA2955384A1 (en) 2016-01-21
BR112017000800A2 (pt) 2018-07-03
JP6706255B2 (ja) 2020-06-03
CN111184733A (zh) 2020-05-22
WO2016011328A1 (en) 2016-01-21
AU2015289504B2 (en) 2020-12-17
EP3628308A1 (en) 2020-04-01
JP2017521499A (ja) 2017-08-03
RU2704811C2 (ru) 2019-10-31
JP2020158507A (ja) 2020-10-01
RU2019133284A (ru) 2019-12-05
RU2017104909A (ru) 2018-08-17
CA2955384C (en) 2024-03-12
CN106604719A (zh) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2017000578A (es) Tratamiento de cancer con una combinacion de radiacion, nanoparticulas de oxido de cerio y un agente quimioterapeutico.
MA39906A (fr) Polythérapies pour le traitement du cancer
CL2017003457A1 (es) Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor.
MX2022008902A (es) Articulo abrasivo que incluye particulas abrasivas conformadas.
MX2017007321A (es) Terapias de combinacion.
PH12017550063A1 (en) Combination therapies for treating cancers
MY188911A (en) Methods of treating bladder cancer
PH12015501486A1 (en) Nanoparticle compositions of albumin and paclitaxel
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
SG10201907684PA (en) Androgen receptor modulator and uses thereof
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2016005710A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX370662B (es) Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
MX2016003653A (es) Virus de mosaico de papaya y particulas similares a virus en terapia de cancer.
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
UY35082A (es) Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof